Compare ASC & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASC | STTK |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 677.7M | 683.8M |
| IPO Year | 2013 | 2020 |
| Metric | ASC | STTK |
|---|---|---|
| Price | $16.78 | $7.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $17.00 | $10.00 |
| AVG Volume (30 Days) | 559.9K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.60 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.17 | $0.71 |
| 52 Week High | $20.03 | $8.33 |
| Indicator | ASC | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 55.43 | 53.08 |
| Support Level | $15.04 | $5.87 |
| Resistance Level | $17.96 | $7.69 |
| Average True Range (ATR) | 0.63 | 0.59 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 68.47 | 43.48 |
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The company markets its services directly to its customers and commercial pool operators and charters its vessels to them through a combination of spot, commercial pooling, and time-charter arrangements. The majority of its revenue is generated from spot voyages, which typically last less than three months.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.